Compare AIXI & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIXI | TARA |
|---|---|---|
| Founded | 2001 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 165.5M |
| IPO Year | 2023 | N/A |
| Metric | AIXI | TARA |
|---|---|---|
| Price | $0.51 | $5.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 226.4K | ★ 1.3M |
| Earning Date | 12-26-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,314,315.00 | N/A |
| Revenue This Year | $26.84 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.84 | N/A |
| 52 Week Low | $0.45 | $2.77 |
| 52 Week High | $6.65 | $7.82 |
| Indicator | AIXI | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 30.27 | 41.28 |
| Support Level | $0.45 | $5.03 |
| Resistance Level | $0.67 | $6.37 |
| Average True Range (ATR) | 0.06 | 0.40 |
| MACD | -0.00 | -0.18 |
| Stochastic Oscillator | 13.86 | 10.43 |
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).